Compare INSG & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INSG | ELOX |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | |
| Sector | Telecommunications | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 60.3M |
| IPO Year | 2000 | 2013 |
| Metric | INSG | ELOX |
|---|---|---|
| Price | $4.33 | $14.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $13.67 | ★ $38.25 |
| AVG Volume (30 Days) | ★ 331.9K | 18.3K |
| Earning Date | 11-05-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.67 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $313,832,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.21 | N/A |
| P/E Ratio | $35.19 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.58 | $10.00 |
| 52 Week High | $21.90 | $23.40 |
| Indicator | INSG | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 47.44 | 39.85 |
| Support Level | $3.96 | $13.92 |
| Resistance Level | $4.61 | $14.65 |
| Average True Range (ATR) | 0.27 | 1.32 |
| MACD | 0.10 | -0.18 |
| Stochastic Oscillator | 57.10 | 21.45 |
Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.